Ultralife (ULBI) Expected to Announce Quarterly Earnings on Monday

Ultralife (NASDAQ:ULBI) is expected to release its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect the company to announce earnings of $0.24 per share and revenue of $57.00 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 7:00 AM ET.

Ultralife (NASDAQ:ULBI) last issued its earnings results on Monday, November 17th. The technology company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.28). The business had revenue of $43.37 million for the quarter, compared to the consensus estimate of $53.00 million. Ultralife had a return on equity of 1.66% and a net margin of 0.92%.

Ultralife Stock Up 0.2%

ULBI stock opened at $5.87 on Friday. Ultralife has a 1-year low of $4.07 and a 1-year high of $9.52. The business’s 50 day simple moving average is $6.16 and its 200 day simple moving average is $6.41. The company has a current ratio of 2.99, a quick ratio of 1.42 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $97.74 million, a PE ratio of 58.70 and a beta of 0.88.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Ultralife in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Insider Transactions at Ultralife

In other Ultralife news, Director Bradford T. Whitmore acquired 28,588 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was purchased at an average price of $5.70 per share, with a total value of $162,951.60. Following the acquisition, the director directly owned 1,235,631 shares of the company’s stock, valued at approximately $7,043,096.70. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 54,750 shares of company stock valued at $310,760. Insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ultralife

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Qube Research & Technologies Ltd bought a new position in shares of Ultralife in the second quarter worth $134,000. Heron Bay Capital Management acquired a new stake in Ultralife during the fourth quarter worth about $127,000. Man Group plc bought a new position in Ultralife in the 3rd quarter valued at about $111,000. Squarepoint Ops LLC bought a new position in Ultralife in the 3rd quarter valued at about $109,000. Finally, Bank of America Corp DE raised its position in shares of Ultralife by 39.9% in the 3rd quarter. Bank of America Corp DE now owns 13,351 shares of the technology company’s stock valued at $91,000 after buying an additional 3,810 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.

About Ultralife

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.